Published in J Endourol on June 01, 2010
Is surgical smoke harmful to theater staff? a systematic review. Surg Endosc (2013) 0.98
Transparent antifouling material for improved operative field visibility in endoscopy. Proc Natl Acad Sci U S A (2016) 0.86
Elimination of laparoscopic lens fogging using directional flow of CO2. JSLS (2014) 0.85
Benchtop evaluation of pressure barrier insufflator and standard insufflator systems. Surg Endosc (2012) 0.81
Electrostatic precipitation is a novel way of maintaining visual field clarity during laparoscopic surgery: a prospective double-blind randomized controlled pilot study. Surg Endosc (2014) 0.77
Shakespeare's view of the laparoscopic pneumoperitoneum. JSLS (2011) 0.76
Humidification during laparoscopic surgery: overview of the clinical benefits of using humidified gas during laparoscopic surgery. Arch Gynecol Obstet (2015) 0.75
Otoscope fogging: examination finding for perforated tympanic membrane. BMJ Case Rep (2014) 0.75
Diathermy awareness among surgeons-An analysis in Ireland. Ann Med Surg (Lond) (2016) 0.75
Alternative agents to prevent fogging in head and neck endoscopy. Clin Med Insights Ear Nose Throat (2011) 0.75
Warmed and humidified carbon dioxide for abdominal laparoscopic surgery: meta-analysis of the current literature. Surg Endosc (2016) 0.75
Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol (2009) 4.07
Active surveillance of small renal masses: progression patterns of early stage kidney cancer. Eur Urol (2011) 3.75
Impact of 5α-reductase inhibitors on men followed by active surveillance for prostate cancer. Eur Urol (2010) 3.41
Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Natl Cancer Inst (2005) 2.99
A new and highly prognostic system to discern T1 bladder cancer substage. Eur Urol (2011) 2.68
Therapeutic options following orchiectomy for stage I seminoma. Oncology (Williston Park) (2009) 2.67
The prostatic urethral lift for the treatment of lower urinary tract symptoms associated with prostate enlargement due to benign prostatic hyperplasia: the L.I.F.T. Study. J Urol (2013) 2.33
Evidence for a biopsy derived grade artifact among larger prostate glands. J Urol (2006) 2.23
Long-term follow-up of T1 high-grade bladder cancer after intravesical bacille Calmette-Guérin treatment. BJU Int (2010) 2.14
Pharmacological approaches to reducing the risk of prostate cancer. Eur Urol (2009) 2.09
Longer wait times increase overall mortality in patients with bladder cancer. J Urol (2009) 2.05
Three year results of the prostatic urethral L.I.F.T. study. Can J Urol (2015) 1.92
Fracture types and risk factors in men with prostate cancer on androgen deprivation therapy: a matched cohort study of 19,079 men. J Urol (2010) 1.87
Is there an optimal comorbidity index for prostate cancer? Cancer (2008) 1.80
Health information quality on the internet in urological oncology: a multilingual longitudinal evaluation. Urology (2009) 1.78
Interobserver variability between expert urologic pathologists for extraprostatic extension and surgical margin status in radical prostatectomy specimens. Am J Surg Pathol (2008) 1.72
Prostatic urethral lift: two-year results after treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urology (2012) 1.71
Treatment of LUTS secondary to BPH while preserving sexual function: randomized controlled study of prostatic urethral lift. J Sex Med (2013) 1.71
Preservation of sexual function with the prostatic urethral lift: a novel treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Sex Med (2011) 1.63
Population based survival data on urachal tumors. J Urol (2006) 1.55
Pathological, oncologic and functional outcomes of radical prostatectomy following active surveillance. J Urol (2013) 1.54
Association of diet-induced hyperinsulinemia with accelerated growth of prostate cancer (LNCaP) xenografts. J Natl Cancer Inst (2007) 1.53
Optimal management of high-risk T1G3 bladder cancer: a decision analysis. PLoS Med (2007) 1.53
Higher surgeon and hospital volume improves long-term survival after radical cystectomy. Cancer (2013) 1.52
Cost-effectiveness analysis of immediate radical cystectomy versus intravesical Bacillus Calmette-Guerin therapy for high-risk, high-grade (T1G3) bladder cancer. Cancer (2009) 1.50
Contemporary management of renal cell carcinoma (RCC) in Victoria: implications for longer term outcomes and costs. BJU Int (2013) 1.50
Measurement of peri-prostatic fat thickness using transrectal ultrasonography (TRUS): a new risk factor for prostate cancer. BJU Int (2012) 1.46
Pathological stage review is indicated in primary pT1 bladder cancer. BJU Int (2009) 1.46
Outcome from percutaneous nephrolithotomy in patients with spinal cord injury, using a single-stage dilator for access. BJU Int (2005) 1.46
Impact of androgen-deprivation therapy on physical function and quality of life in men with nonmetastatic prostate cancer. J Clin Oncol (2010) 1.45
Patterns of care for men diagnosed with prostate cancer in Victoria from 2008 to 2011. Med J Aust (2013) 1.43
Demographic analysis: an update of randomized controlled studies in prostatic oncology. Can Urol Assoc J (2011) 1.42
Renal colic: current protocols for emergency presentations. Eur J Emerg Med (2016) 1.42
Radical prostatectomy in obese patients: Improved surgical outcomes in recent years. Int J Urol (2010) 1.41
Clinical predictors of Gleason score upgrading: implications for patients considering watchful waiting, active surveillance, or brachytherapy. Cancer (2007) 1.35
Is there age bias in the treatment of localized prostate carcinoma? Cancer (2004) 1.29
PTEN losses exhibit heterogeneity in multifocal prostatic adenocarcinoma and are associated with higher Gleason grade. Mod Pathol (2012) 1.26
Association of tissue promoter methylation levels of APC, TGFβ2, HOXD3 and RASSF1A with prostate cancer progression. Int J Cancer (2011) 1.25
Mobile phone interference with medical equipment and its clinical relevance: a systematic review. Med J Aust (2004) 1.22
Anastomosing haemangioma of the kidney: a rare morphological variant of haemangioma characteristic of genitourinary tract location. Pathology (2013) 1.19
Surgical margin status among men with organ-confined (pT2) prostate cancer: a population-based study. Can Urol Assoc J (2011) 1.17
Sclerosing lipogranuloma of the genitalia treated with corticosteroids. Int Urol Nephrol (2006) 1.16
The continuing importance of transrectal ultrasound identification of prostatic lesions. J Urol (2007) 1.16
Modulation of cell proliferation and cell cycle regulators by vitamin E in human prostate carcinoma cell lines. J Urol (2002) 1.13
Multidetector computed tomography vs magnetic resonance imaging for defining the upper limit of tumour thrombus in renal cell carcinoma: a study and review. BJU Int (2005) 1.11
Urologists in cyberspace: A review of the quality of health information from American urologists' websites using three validated tools. Can Urol Assoc J (2013) 1.07
Experience and attitudes of final-year medical students to digital rectal examination. Med J Aust (2004) 1.04
Selenium modulation of cell proliferation and cell cycle biomarkers in human prostate carcinoma cell lines. Cancer Res (2002) 1.04
Positron emission tomography and molecular imaging of the prostate: an update. BJU Int (2006) 1.03
Antioxidants block prostate cancer in lady transgenic mice. Cancer Res (2004) 1.03
The FGFR3 mutation is related to favorable pT1 bladder cancer. J Urol (2011) 1.03
DNA methylation of HOXD3 as a marker of prostate cancer progression. Lab Invest (2010) 1.01
Patients with Lynch syndrome mismatch repair gene mutations are at higher risk for not only upper tract urothelial cancer but also bladder cancer. Eur Urol (2012) 1.00
Nutraceuticals and prostate cancer prevention: a current review. Nat Rev Urol (2009) 1.00
Operator is an independent predictor of detecting prostate cancer at transrectal ultrasound guided prostate biopsy. J Urol (2009) 1.00
Comparison of risk calculators from the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer in a contemporary Canadian cohort. BJU Int (2011) 0.98
Assessing regional hypoxia in human renal tumours using 18F-fluoromisonidazole positron emission tomography. BJU Int (2005) 0.97
A combination of micronutrients is beneficial in reducing the incidence of prostate cancer and increasing survival in the Lady transgenic model. Cancer Prev Res (Phila) (2009) 0.96
The REDUCE trial: chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride. Expert Rev Anticancer Ther (2008) 0.94
Select screening in a specific high-risk population of patients suggests a stage migration toward detection of non-muscle-invasive bladder cancer. Eur Urol (2011) 0.93
Prognostic value of molecular markers, sub-stage and European Organisation for the Research and Treatment of Cancer risk scores in primary T1 bladder cancer. BJU Int (2012) 0.91
The effects of nonspecific HIF1α inhibitors on development of castrate resistance and metastases in prostate cancer. Cancer Med (2014) 0.91
Positron emission tomography (PET), immuno-PET and radioimmunotherapy in renal cell carcinoma: a developing diagnostic and therapeutic relationship. BJU Int (2006) 0.91
The management of BCG failure in non-muscle-invasive bladder cancer: an update. Can Urol Assoc J (2009) 0.91
Analytical accuracy and reliability of commonly used nutritional supplements in prostate disease. J Urol (2002) 0.90
Phosphodiesterase 5 inhibitors in the management of benign prostatic hyperplasia and erectile dysfunction: the best of both worlds. Curr Opin Urol (2009) 0.90
Investigation of hypoxia and carbonic anhydrase IX expression in a renal cell carcinoma xenograft model with oxygen tension measurements and ¹²⁴I-cG250 PET/CT. Urol Oncol (2009) 0.90
Oral contraceptive use is associated with prostate cancer: an ecological study. BMJ Open (2011) 0.90
Positive surgical margins: rate, contributing factors and impact on further treatment: findings from the Prostate Cancer Registry. BJU Int (2014) 0.89
Varied definitions of hospital volume did not alter the conclusions of volume-outcome analyses. J Clin Epidemiol (2008) 0.89
Detection of urothelial tumors: comparison of urothelial phase with excretory phase CT urography--a prospective study. Radiology (2012) 0.89
An analysis of world media reporting of two recent large randomized prospective trials investigating screening for prostate cancer. BJU Int (2011) 0.88
Improved assessment of renal lesions in pregnancy with magnetic resonance imaging. Urology (2009) 0.88
Neoadjuvant radiotherapy for locally advanced and high-risk prostate cancer. Nat Rev Clin Oncol (2010) 0.88
Quantitative DNA methylation analysis of genes coding for kallikrein-related peptidases 6 and 10 as biomarkers for prostate cancer. Epigenetics (2012) 0.88
MicroRNA signature helps distinguish early from late biochemical failure in prostate cancer. Clin Chem (2013) 0.88
An update on chemoprevention strategies in prostate cancer for 2006. Curr Opin Urol (2006) 0.88
Fine-needle aspiration cytology predicts inguinal lymph node metastasis without antibiotic pretreatment in penile carcinoma. BJU Int (2006) 0.85
Cystoscopy in women with recurrent urinary tract infection. Int J Urol (2006) 0.85
Nonprimary pT1 nonmuscle invasive bladder cancer treated with bacillus Calmette-Guerin is associated with higher risk of progression compared to primary T1 tumors. J Urol (2010) 0.85
Upstaging of urothelial cancer at the time of radical cystectomy: factors associated with upstaging and its effect on outcome. BJU Int (2012) 0.85
Results of high intensity focused ultrasound treatment of prostate cancer: early Canadian experience at a single center. Can J Urol (2011) 0.84
Recovery of erectile function after unilateral and bilateral cavernous nerve interposition grafting during radical pelvic surgery. J Urol (2009) 0.84
Functional imaging of renal cell carcinoma. Nat Rev Urol (2010) 0.84
Prostate cancer immunology - an update for Urologists. BJU Int (2010) 0.83
Diagnostic and therapeutic use of radioisotopes for bony disease in prostate cancer: current practice. Int J Urol (2007) 0.82
Health-related quality of life following radical prostatectomy: long-term outcomes. Qual Life Res (2014) 0.80
Implications of amyloidosis on prostatic biopsy. Int J Urol (2004) 0.80
Prehabilitation for men undergoing radical prostatectomy: a multi-centre, pilot randomized controlled trial. BMC Surg (2014) 0.80
FGFR3 mutations, but not FGFR3 expression and FGFR3 copy-number variations, are associated with favourable non-muscle invasive bladder cancer. Virchows Arch (2014) 0.79
Dutasteride and active surveillance of low-risk prostate cancer. Lancet (2012) 0.79
Lymph node assessment and lymphadenectomy in bladder cancer. J Surg Oncol (2009) 0.79
Does nerve-sparing radical prostatectomy increase the risk of positive surgical margins and biochemical progression? Urol Ann (2010) 0.79
Preoperative evaluation of the "hostile pelvis" in radical prostatectomy with computed tomographic pelvimetry. BJU Int (2006) 0.79
Detection of infectious organisms in archival prostate cancer tissues. BMC Cancer (2014) 0.79
Predicting prostate biopsy outcome: artificial neural networks and polychotomous regression are equivalent models. Int Urol Nephrol (2010) 0.79
Fas-mediated killing of primary prostate cancer cells is increased by mitoxantrone and docetaxel. Mol Cancer Ther (2008) 0.78
Integration of laparoscopic partial nephrectomy into an Australian public hospital: three-year follow-up of our initial 50 cases. BJU Int (2012) 0.78
Sex differences in bladder cancer outcomes among smokers with advanced bladder cancer. BJU Int (2011) 0.77